Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents to Report Third Quarter 2024 Operating and Financial Results

CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
October 01, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
August 07, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

CytoSorbents to Report Q2 2024 Financial and Operating Results
August 01, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents regains compliance with Nasdaq minimum bid price requirement
May 02, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
April 17, 2024 07:00 ET | Source: CytoSorbents

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
December 28, 2023 07:00 ET | Source: CytoSorbents

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
December 13, 2023 09:15 ET | Source: CytoSorbents

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
October 05, 2023 07:00 ET | Source: CytoSorbents

CytoSorbents to Present at the 8th Annual Dawson James Conference

CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
July 07, 2023 07:07 ET | Source: CytoSorbents

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...